The case for & against
Bull & Bear analysis
Bearish
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is a clinical-stage biotechnology company focused on discovering and developing targeted therapeutics for cancer. The company is particularly noted for its innovative pipeline, including treatments for MTAP-deleted cancers, such as pancreatic and lung cancer, positioning itself as a significant player within the precision medicine segment of oncology. Given today's rising demand for personalized therapies, IDEAYA is directly engaged in a relevant and transformative theme in the healthcare sector.
Bull says
- ↑Initiation of Phase 1/2 IDE892 study targets MTAP-deleted pancreatic and lung cancers.
- ↑$1.1B in cash and marketable securities as of Sep 30, 2025 funds operations into 2030.
- ↑Analyst consensus is Moderate Buy with a $50.25 average price target (~35.8% upside).
- ↑High institutional interest—strong 13F ownership suggests investor confidence.
- ↑Positive market sentiment (~59% positive factors) and solid balance sheet qualities.
- ↑Stable liquidity factor supports smoother trading and entry opportunities.
Bear says
- ↓Negative earnings yield and weak profitability indicate ongoing losses.
- ↓Leverage risk elevated, raising concerns over debt servicing without cash flow.
- ↓Negative growth and analyst revision trends signal faltering revenue outlook.
- ↓CAO sold $382K of stock, hinting at internal apprehension.
- ↓Stock down 2.3% in recent session, reflecting bearish sentiment.
- ↓Poor factor scores in growth, revisions, and profitability underscore headwinds.
Investment themes with IDYA
Biotech↓ -3.20%
Genetic and drug innovations driving medical breakthroughs
APLS · RVMD · SMMT